Atrium Therapeutics, Inc.
corporate_fare Company Profile
Atrium Therapeutics, Inc. (NASDAQ:RNA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for RNA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 10/10, with 14 rated 8 or above. Recent SEC coverage for RNA spans 8-K, 10-Q, 10-K, DEFA14A.
Recent high-impact activity:
- Atrium Therapeutics Posts 25-Cent Quarterly Loss as Cash Burn Draws Scrutiny
- Activist Yakira Demands Strategic Review at Atrium, Says Stock Trades Below Net Cash
- Atrium Therapeutics Prices $50M PIPE at $7.93/Share, Extends Runway Through 2028
- Atrium Therapeutics Raises $50M in Private Placement Near 52-Week Low
- FDA Clears Atrium's IND for ATR 1072, Phase 1/2 Trial to Start
Short Interest & Short Volume
16.07 days to coverFINRA reported short interest of 3,749,186 shares in RNA as of the October 30, 2026 settlement, a 0.6% increase from the prior period — about 16.1 days to cover at its recent average daily volume. On November 20, 2026, 62.5% of RNA volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for RNA, detected from its recent SEC filings · based on capital-structure filings through 2026-10-09.
Post-Offering Share Count Corrected · PIPE Terms Reaffirmed
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →